THERAPEUTICS
Influenza immunisation during pregnancy reduced influenza in infants and respiratory illness in mothers
| The first 150 words of the full text of this article appear below. |
M C Steinhoff
Dr M C Steinhoff, Cincinnati Childrens Hospital, Cincinnati, OH, USA; m.steinhoff@gmail.com
STUDY DESIGN
randomised pneumococcal vaccine-controlled trial. ClinicialTrials.gov NCT00142389 [ClinicalTrials.gov] .
concealed.*
blinded {patients, clinicians, data collectors, outcome assessors, data analysts, and safety committee}
.*
STUDY QUESTION
Bangladesh.
340 mothers 18–36 years of age (mean age 25 y) in the third trimester of pregnancy. Exclusion criteria were history of systemic disease, previous complicated pregnancy or preterm delivery, abortion, congenital anomaly, or hypersensitivity to study vaccines in the past 3 years.
inactivated influenza vaccine (n = 172) or 23-valent pneumococcal polysaccharide vaccine (n = 168). The influenza vaccine contained strains from 2004 as recommended by the World Health Organization, including A/New Caledonia/20/99 (H1N1), A/Fujian/411/2002 (H3N2), and B/Hong Kong/330/2001.
included first episode of laboratory-confirmed influenza in infants, and respiratory illness with any fever or fever >38°C, clinic visits for respiratory illness, and diarrhoea in both mothers and infants.
24 weeks after birth.
93% (intention-to-treat
University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
